Updated:
Evofem Biosciences
Evofem Biosciences is a biotechnology company based in San Diego, United States, founded in 2009. It develops reproductive and contraceptive care products for...
Evofem Biosciences
Evofem Biosciences is a biotechnology company based in San Diego, United States, founded in 2009. It develops reproductive and contraceptive care products for women globally. The company has secured $112.8 million in total funding.
General information
Firm type
other
Year founded
1995
Location
Region
North America
Country
United States
City
San Diego
Corporate office
San Diego, CA, United States
Sector focus
Frequently asked questions
Who runs investment decisions at Evofem?
Evofem Biosciences is a publicly traded company. Investment decisions, including capital allocation for R&D and commercial activities, are made by the board of directors and management team, led by CEO Saundra Pelletier. The company does not function as a family office; its operations are governed by SEC disclosure rules.
How does Evofem source proprietary deal flow?
Evofem sources deal flow through licensing agreements, partnerships, and co-promotion deals within the biotech and pharmaceutical sectors. For example, it has partnered with AMAG Pharmaceuticals for co-promotion of Phexxi (per SEC filing, 2020). The firm's pipeline includes in-licensed candidates, though it does not disclose a proprietary sourcing method.
Does Evofem participate in fund commitments or only direct deals?
Evofem does not participate in fund commitments as an LP. As a public company, its capital is raised through equity offerings, debt, and revenue from product sales. It engages in direct licensing and partnership deals for its pipeline assets.
Which sectors does Evofem explicitly avoid?
Evofem focuses exclusively on women's sexual and reproductive health. It avoids oncology, cardiovascular, neurology, and other therapeutic areas. The company's pipeline is centered on non-hormonal contraception, infection prevention, and reproductive health, as stated in its public filings.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: